IngredientsIsomaltase is a digestive enzyme classified under the Enzyme Commission (EC) number EC 3.2.1.10 and is formally designated as oligo-1,6-glucosidase or α-dextrinase. There are four relevant types of digestive α-glucosidases in humans: maltase (α-1,4-glucosidase; EC 3.2.1.20), glucoamylase (exo-1,4-α-glucosidase; EC 3.2.1.3), sucrase (α-glucohydrolase; EC 3.2.1.48), and isomaltase (oligo-1,6-glucosidase or α-dextrinase; EC 3.2.1.10). In vivo, isomaltase does not exist as a standalone entity but is the N-terminal catalytic subunit of the larger bifunctional protein complex known as sucrase-isomaltase (SI).
Sucrase-isomaltase is a bifunctional glucosidase located on the brush border of the small intestine, encoded by the human gene SI. It is a dual-function enzyme with two GH31 domains, one serving as the isomaltase, the other as a sucrose alpha-glucosidase. The gene encoding sucrase-isomaltase is located on chromosome 3q26.1. The genes encoding SI and MGAM (maltase-glucoamylase) are located on chromosome 3 (3q26.1) and chromosome 7 (7q34), respectively. SI and MGAM are members of the glycosyl hydrolase family 31 (GH31), with a remarkable 58% identity in their amino acid sequence.
The isomaltase subunit is formed from the precursor protein pro-sucrase-isomaltase (pro-SI). Sucrase-isomaltase is synthesized and assembled in the rough endoplasmic reticulum as a homologous pro-enzyme dimer which passes through the Golgi apparatus and is transported to the apical cell surface of villi. There, it is cleaved into its mature subunits, sucrase and isomaltase, by pancreatic proteases. Upon maturation in the enterocytes and proper sorting to the apical membrane, SI is cleaved in the intestinal lumen by pancreatic trypsin to its two subunits sucrase (SUC) and isomaltase (IM), which remain associated with each other via strong ionic interactions.
The primary structure of the pro-SI protein has been extensively characterized. The complete primary structure (1827 amino acids) of rabbit intestinal pro-sucrase-isomaltase (pro-SI) was deduced from the sequence of a nearly full-length cDNA. Pro-SI is anchored in the membrane by a single 20 amino acid segment spanning the bilayer only once. The amino-terminal, cytoplasmic domain consists of 12 amino acids and is not preceded by a cleaved leader sequence. A 22 residue serine/threonine-rich, probably glycosylated, stretch follows, presumably forming the stalk on which the globular, catalytic domains are directed into the intestinal lumen. There is a high degree of homology between the isomaltase and sucrase portions (41% amino acid identity), indicating that pro-SI evolved by partial gene duplication.
The enzyme is anchored in the intestinal brush border membrane by a hydrophobic segment located near the N-terminus of the isomaltase subunit. The isomaltase domain therefore serves a dual purpose: it provides the membrane anchor for the entire SI complex, and it contains an independent catalytic site responsible for hydrolyzing alpha-1,6-glycosidic bonds. The N-terminal SI (ntSI) and C-terminal SI (ctSI) subunits have additional activity for the α-1,6 linkages of starch branch points (and isomaltose substrates) and the α-1,2 linkage of sucrose, respectively, and are historically referred to as isomaltase and sucrase.
Isomaltase activity, as part of the sucrase-isomaltase complex, is an endogenous human enzyme — it is produced within the body and is not derived from an exogenous botanical or food source in the conventional sense of a dietary supplement ingredient. The sucrase-isomaltase enzyme is found on the surface of the intestinal epithelial cells, which are cells that line the walls of the intestine. These cells have fingerlike projections called microvilli that absorb nutrients from food as it passes through the intestine. Based on their appearance, groups of these microvilli are known collectively as the brush border.
It has preferential expression in the apical membranes of enterocytes. These intermediate by-products of partial starch digestion must undergo further enzymatic hydrolysis at the apical enterocyte surface to monosaccharides by expressed sucrase-isomaltase (SI), maltase-glucoamylase (MGAM), and lactase. These enzymes, along with trehalase (a minor player), are continuously produced by healthy luminal enterocytes that constitute the apical mucosal surface, also referred to as the brush border.
When used as a therapeutic or supplemental agent, isomaltase activity is delivered indirectly. No enzyme replacement therapy for patients with congenital sucrase-isomaltase deficiency existed for a considerable period; a by-product of the manufacture of baker's yeast is a liquid preparation containing high sucrase activity. Treatment for the condition consists of sacrosidase, obtained from baker's yeast and glycerin, which is the only Food and Drug Administration (FDA)-approved treatment for this condition. Notably, Sucraid (sacrosidase) does not contain isomaltase. The approved therapeutic therefore supplies only the sucrase component; the isomaltase component of the complex has no equivalent approved exogenous preparation. There is no FDA-approved isomaltase-only therapy. Approved enzyme therapy targets sucrase (sacrosidase) for CSID; dietary management remains central for alpha-1,6 intolerance features.
In the context of over-the-counter enzyme supplements, over-the-counter blends often list "alpha-glucosidase" from fungal or plant sources. These may provide broad activity against alpha-1,4 bonds and, to varying degrees, alpha-1,6 bonds. However, the amount of active enzyme, pH stability in the stomach, and precise activity against limit dextrins differ widely across products and are rarely standardized to clinical endpoints.
Isomaltase, as an isolated biochemical entity, has no direct history of traditional use. The enzyme was not known or intentionally administered in any historical healing tradition, as its existence and function were defined only through twentieth-century biomedical research. However, recognition of the clinical syndromes attributable to its deficiency has a documented history within medicine.
The first formal scientific descriptions of disaccharidase deficiencies, including sucrase-isomaltase deficiency, emerged in the early 1960s. The condition was identified as a cause of chronic childhood diarrhea. Genetic sucrase-isomaltase deficiency (GSID) is an inherited deficiency in the ability to digest sucrose and potentially starch due to mutations in the sucrase-isomaltase (SI) gene. Congenital sucrase-isomaltase deficiency is historically considered to be a rare condition affecting infants with chronic diarrhea as exposure to dietary sucrose begins.
Epidemiological research revealed a strikingly high prevalence of the condition in certain Arctic indigenous populations, underscoring an important gene-environment interaction. Although the condition is known to be highly prevalent (about 5%–10%) in several Inuit populations, the genetic basis for this had not originally been described. One research project started when an Inuit baby girl from Baffin Island experienced severe diarrhea and abdominal distension in hospital after consuming formula containing sucrose. This observation prompted deeper investigation into the molecular genetics of the Inuit population's high burden of the disease.
The early therapeutic approach, prior to formal enzyme replacement, was purely dietary: restricting sucrose and starch intake in affected infants and children. Investigation into yeast-derived enzyme preparations as a treatment for CSID began in earnest in the 1980s and 1990s. One early study investigated the activity and stability of a yeast-derived preparation and its effect on breath hydrogen excretion and gastrointestinal symptoms after sucrose ingestion in 14 patients with CSID. This work ultimately led to the development and regulatory approval of sacrosidase (Sucraid).
The isomaltase subunit plays an indispensable and unique role in the final stages of starch digestion. The salivary and pancreatic α-amylases hydrolyze starch molecules to linear malto-oligosaccharides (consisting mainly of maltose and maltotriose) and α-1,6-branched oligosaccharides (α-limit dextrins), which cannot be further hydrolyzed by the α-amylases. The mixture of linear malto-oligosaccharides and branched α-limit dextrins must be further hydrolyzed to glucose by the combined exohydrolytic actions of maltase-glucoamylase (MGAM) and sucrase-isomaltase (SI) enzyme complexes in the small intestine.
The specific and exclusive biochemical role of isomaltase is the cleavage of alpha-1,6-glycosidic bonds. Isomaltase is the only enzyme able to hydrolyze the α-1,6-glycosidic linkage in α-limit dextrins to produce glucose. The isomaltase component of the SI complex hydrolyzes α-1,6 linkages of the α-limit dextrins after primary luminal pancreatic amylase has reduced the ingested starch to soluble subunits. In structural terms, the N-terminal domain of sucrase-isomaltase (NtSI) cleaves the α-(1,6) linkage of amylopectin, while the C-terminal domain of sucrase-isomaltase (CtSI) is able to cleave the α-(1,2) linkage of sucrose.
The SI complex additionally contributes substantial maltase activity to the small intestine. The SI complex is composed of two α-glucosidase units, sucrase and isomaltase. The isomaltase component demonstrates considerable α-glycosidic activity on starch-derived glucose oligomers, and the SI complex together contributes to 60 to 80 percent of total intestinal maltase activity. All four subunits of the mucosal α-glucosidase complexes have α-1,4-exohydrolytic glucosidase activity, and the SI N-terminal subunit has an additional exo-debranching activity on the α-1,6-linkage.
Research has further established that SI and its partner enzyme MGAM interact physically within the brush border membrane. The potential interaction between SI and MGAM was investigated in solubilized brush border membranes utilizing reciprocal pull-down assays. The results demonstrate that SI interacts avidly with MGAM concomitant with a hetero-complex assembly in the brush border membranes. In view of their interaction, SI and MGAM regulate the final steps in starch digestion in the intestine, whereby SI assumes the major role by virtue of its predominant expression in the intestinal brush border membranes, while MGAM acts in an auxiliary supportive fashion.
SI and MGAM in combination comprise about 11% of total intestinal brush border membrane (BBM) proteins, whereby SI expression level is almost three-fold higher than that of MGAM. SI is capable of digesting α-1,4, α-1,6, and α-1,2 glycosidic linkages. With almost 80% digestive capacity of α-1,4 glycosidic linkages, SI has been proposed to contribute substantially to mucosal MGAM activity. SI is also exclusively responsible for sucrose digestion and all isomaltase (1,6-O-α-d-glucanohydrolase) activity.
The isomaltase subunit is classified among the intestinal maltase activities. Four enzymes have been identified as different maltases, exo-glucosidases bound to the luminal surface of enterocytes. Two of these maltase activities were associated with sucrase-isomaltase (maltase Ib, maltase Ia). The other two maltases with no distinguishing characteristics were named maltase-glucoamylase (maltases II and III). The activities of these four maltases are also described as alpha-glucosidase because they all digest linear starch oligosaccharides to glucose.
Released monosaccharides, mostly free glucose, enter the absorbing enterocyte at the apical surface by specific transport mechanisms and are distributed to the body. The enzyme's purpose is to digest dietary carbohydrates such as starch, sucrose, and isomaltose. By further processing the broken-down products, energy in the form of ATP can be generated.
When isomaltase function is absent or reduced, the undigested α-limit dextrins and sucrose pass into the large intestine. The accumulation of undigested carbohydrates in the intestines is the cause of osmotic diarrhea, and their fermentation by colon bacteria leads to the release of large amounts of hydrogen and other gases, which is accompanied by significant bloating and flatulence.
Congenital sucrase-isomaltase deficiency (CSID) is an autosomal recessive human intestinal disorder that is clinically characterized by fermentative diarrhea, abdominal pain, and cramps upon ingestion of sugar. The symptoms are the consequence of absent or drastically reduced enzymatic activities of sucrase and isomaltase, the components of the intestinal integral membrane glycoprotein sucrase-isomaltase (SI).
Genetic sucrase-isomaltase deficiency (GSID) is an inherited deficiency in the ability to digest sucrose and potentially starch due to mutations in the sucrase-isomaltase (SI) gene. The mutational landscape is complex. Mutations C1229Y and F1745C, which are present in the sucrase domain of SI, block SI's path to anchor in the cell's apical membrane but do not impact protein folding or isomaltase activity. Substitution of a cysteine by an arginine at amino acid residue 635 in the isomaltase subunit of SI was present in the cDNA encoding for a patient with CSID. This variant had an altered folding pattern, which influenced the sorting profile and increased the turnover rate. Notably, patients with CSID generally have reduced sucrase activity, but levels of isomaltase activity range from absent to almost normal.
Growing evidence suggests that individuals with SI variants may present later in life, with symptoms overlapping with those of irritable bowel syndrome. The presence of SI genetic variants may, either alone or in combination, affect enzyme activity and lead to symptoms of different severity. As such, a more appropriate term for this inherited condition is GSID, with a recognition of a spectrum of severity and onset of presentation.
The clinical expression of CSID/GSID ranges considerably by age of presentation and severity. In infants, CSID classically presents as explosive watery diarrhea, failure to thrive, diaper rash, irritability, and acidic stools. In adolescents and adults, CSID has been characterized by symptoms of bloating, gas, diarrhea, abdominal cramps, and nausea, which overlap with common irritable bowel syndrome (IBS) symptoms. Before receiving the ultimate diagnosis, many other conditions were ruled out, most frequently celiac disease, followed by lactose intolerance. For adults specifically, irritable bowel syndrome (IBS) was ruled out most frequently.
CSID has been historically considered a rare disease, with an estimated 0.2% prevalence in North American and European populations and an even lower prevalence in African Americans and whites of Hispanic descent. Higher estimates have been reported among certain populations, with one study reporting a 10% prevalence among Inuit communities in Greenland.
Recent clinical and genetic studies suggest that CSID is a more common disease than previously thought. Clinical studies of smaller populations have found a high prevalence of CSID: 5% in indigenous Greenlanders, 7% of Canadian Inuit populations, and 3% in indigenous Alaskans. The genetic basis for the elevated Inuit prevalence has been identified: a novel, homozygous frameshift mutation, c.273_274delAG (p.Gly92Leufs*8), predicted to result in complete absence of a functional protein product, was identified. This change was very common among Inuit controls, with an observed allele frequency of 17.2% (95% CI 12.6%–21.8%). The predicted Hardy-Weinberg prevalence of CSID in Inuit people, based on this single founder allele, is 3.0% (95% CI 1.4%–4.5%). A common mutation, SI c.273_274delAG, was found to be responsible for the high prevalence of CSID among Inuit people.
Genetic variants causing loss of sucrase-isomaltase (SI) function result in malabsorption of sucrose and starch components and the condition CSID. The identified genetic variants causing CSID are very rare in all surveyed populations around the globe, except the Arctic-specific c.273_274delAG loss-of-function (LoF) variant, which is common in the Greenlandic Inuit and other Arctic populations. One unexpected finding from the Greenlandic population studies was that a recent study of the LoF variant in Greenlanders reported that adult homozygous carriers have a markedly healthier metabolic profile.
A deficiency in the SI enzyme can be present at birth (genetic) or acquired later, often in association with damage to the enteric brush-border membrane. Secondary or acquired sucrose intolerance is more common than CSID and occurs as a result of mucosal damage and brush border injury from organic causes. Classic symptoms of diarrhea-predominant IBS (IBS-D) also occur with secondary SID, when the intestinal mucosa has been damaged by infectious or autoimmune disorders such as giardiasis or celiac disease.
Mucosal enzyme activity is frequently reduced in states of inflammation, functional bowel disorders, malnutrition, and mucosal injury, and this is a largely unaddressed therapeutic concern. Additionally, certain pharmaceutical agents can heavily inhibit SI and result in gastrointestinal symptoms. For example, N-butyldeoxynojirimycin (miglustat), used for treatment of lysosomal storage diseases, can heavily inhibit SI. Codeine as a pain medication and ranitidine with antihistamine effect can also inhibit sucrase activity in the intestine. Furthermore, several herbal folk remedies, especially those with polyphenolic components, also exert an inhibitory effect on SI.
Several publications reported an increased prevalence of hypomorphic (defective) sucrase-isomaltase (SI) gene variants in patients with irritable bowel syndrome (IBS), and the association with impaired cell-surface expression and reduced digestive function of the corresponding enzyme. In addition, hypomorphic SI carriers showed reduced response compared with non-carriers in a low-FODMAP trial of IBS patients with diarrhoea.
Some patients diagnosed with IBS may be predisposed to sucrase deficiency caused by CSID. Two large studies reported that, while relatively rare, sucrase-isomaltase (SI) variants are more common among adults diagnosed with IBS. The first study, which compared 2146 IBS-diagnosed patients with a large, ethnically-matched reference population, found evidence linking SI variants with IBS susceptibility.
Currently, disaccharidase assay on duodenal mucosal tissue homogenates is the gold standard in diagnosing SI deficiency. Confirmation is by disaccharidase assay of duodenal or jejunal mucosa obtained endoscopically. Other noninvasive diagnostic alternatives such as sucrose breath tests may be useful but require further validation. Falsely low enzyme activities may result from technical factors such as inadequate freezing, or from secondary causes including mucosal inflammation, celiac disease, or intestinal infections.
The most robustly supported clinical evidence for addressing sucrase-isomaltase deficiency relates to exogenous enzyme replacement targeting the sucrase component (sacrosidase). Evidence in one controlled trial in primarily pediatric patients shows that Sucraid is safe and effective for the treatment of the genetically acquired sucrase deficiency, which is part of CSID.
The pivotal evidence base for sacrosidase was established in two multicenter randomized trials. In two multicenter, double-blind, randomized trials of sacrosidase treatment, 81% of patients were asymptomatic while on an unrestricted diet. Both sucrose hydrogen breath test and 13C-sucrose breath tests normalized with sacrosidase.
An earlier double-blind placebo-controlled study with 14 CSID patients reported detailed outcome data. Breath Hâ‚‚ excretion decreased significantly when patients received sacrosidase or sacrosidase plus milk compared to placebo during sucrose breath tests. During the dose-response phase, significant treatment differences were observed between the two higher concentrations and the two lower concentrations of sacrosidase for both total stools (p < 0.001) and total symptom score (p = 0.003). Higher concentrations of sacrosidase were associated with fewer stools and a greater number of formed or hard stools compared to lower concentrations and compared to the baseline period. Higher concentrations were also associated with fewer symptoms of gas, abdominal cramps, or bloating, but no differences in vomiting.
A case series of six patients documented the practical clinical benefit: all six patients showed little improvement following advice regarding dietary management, but experienced a marked reduction in symptoms with sacrosidase administration; no adverse events were reported.
Liquid yeast sucrase offers effective enzyme replacement therapy for patients with CSID. An adult case study further illustrated the benefit: formal dietary reduction of starches and sucrose was associated with a 50% symptom response, and a therapeutic trial of sacrosidase led to complete resolution of symptoms. Withholding then reinstituting sacrosidase verified response to it.
Evidence strength for sacrosidase in CSID: Moderate-to-strong. There are double-blind, placebo-controlled trials and multicenter randomized data supporting efficacy for the sucrase component. However, it is important to note that the approved therapy (sacrosidase) does not supply isomaltase, meaning the starch intolerance component associated with isomaltase deficiency is not directly treated by sacrosidase. Management of GSID is based on sucrose and potentially starch restriction tailored to the individual patients' tolerance and symptoms. As this approach may be challenging, additional treatment with commercially available sacrosidase is available. However, some patients may require continued starch restriction.
Growing evidence suggests that individuals with SI variants may present later in life, with symptoms overlapping with those of irritable bowel syndrome. While a few CSID cases have also been described in adults, there is accumulating evidence that partial SI deficiency (possibly as in hypomorphic carriers) is associated with increased risk of IBS in the general population. Hence, a clinical continuum across sucrose and starch malabsorption may be envisaged, which spans a spectrum of functionally diverse DNA variations in the SI gene.
Recent investigations are providing evidence that sucrase-isomaltase deficiency is more prevalent and of greater clinical significance than previously suspected. Further research is required to correlate the specific genotypes and phenotypes with their clinical expressions and to determine the most appropriate treatment algorithm for these patients.
Evidence strength: Preliminary. The association between SI gene variants and IBS risk is supported by large genetic studies, but causal and therapeutic trials specifically targeting the IBS-SI variant population are limited.
The isomaltase domain of the SI complex is a recognized pharmacological target in the management of type 2 diabetes, specifically via inhibition rather than supplementation. Acarbose is a complex oligosaccharide produced in bacteria that has activity against glucoamylase, sucrase, maltase, and isomaltase, intestinal brush border glucosidases. The inhibition of glucosidase activity blocks the breakdown of starch and disaccharides to absorbable monosaccharides, leading to a delay in glucose absorption and a degree of carbohydrate malabsorption which results in a blunting of the postprandial rise in blood glucose.
Alpha-glucosidase inhibitors inhibit the absorption of carbohydrates from the small intestine. They competitively inhibit enzymes that convert complex nonabsorbable carbohydrates into simple absorbable carbohydrates. These enzymes include glucoamylase, sucrase, maltase, and isomaltase. Standardized inhibitory data from human cell-derived enzyme preparations show: acarbose inhibited sucrase, maltase, and isomaltase with IC₅₀ values of 1.65, 13.9, and 39.1 µM, respectively.
As they are involved in the breakdown of dietary sugars and starches, MGAM and SI are attractive targets for inhibition by α-glucosidase inhibitors as a means of controlling blood glucose levels in individuals with type 2 diabetes.
Evidence strength: Strong for acarbose as an inhibitor of isomaltase in the type 2 diabetes context. This evidence supports the physiological relevance of isomaltase in glucose homeostasis, but represents therapeutic inhibition of the enzyme, not supplementation.
For patients with CSID, prescription sucrase replacement (sacrosidase) has solid support: clinical trials show it helps children with CSID tolerate sucrose-containing meals with far fewer symptoms. OTC blends sometimes include invertase, but there is little direct research showing meaningful benefits in people with normal sucrase–isomaltase activity. Meaningful benefits stem from a clear diagnosis, strategic carbohydrate dosing, and—in selected genetic cases—prescription enzyme replacement for the sucrase component. Consumer enzyme blends may help some individuals, but responses are inconsistent and should be viewed as adjuncts to, not replacements for, proper evaluation and diet planning.
Evidence strength: Absent to negligible for isomaltase supplementation in individuals without a diagnosed deficiency. No controlled human trials have evaluated commercial isomaltase-containing supplements in the general population.
As noted, there is no approved exogenous isomaltase preparation. The closest clinical analog is sacrosidase (Sucraid), which supplies sucrase activity from Saccharomyces cerevisiae and addresses the sucrase component of CSID. The following dosage information pertains specifically to this agent as reported in clinical trials and FDA labeling:
Regarding dose form standardization in over-the-counter products: OTC blends may provide broad activity against alpha-1,4 bonds and, to varying degrees, alpha-1,6 bonds. However, the amount of active enzyme, pH stability in the stomach, and precise activity against limit dextrins differ widely across products and are rarely standardized to clinical endpoints.
Adverse experiences with Sucraid in clinical trials were generally minor and were frequently associated with mild reactions. Overdosage with Sucraid has not been reported. In the primary dose-response trial, the only significant adverse event was wheezing in one child with a history of asthma. Sacrosidase is a safe, effective, well-accepted treatment to prevent gastrointestinal symptoms in patients with CSID consuming a normal diet.
A critical safety and efficacy caveat is that sacrosidase addresses only the sucrase component of CSID. Sucraid (sacrosidase) does not contain isomaltase. Sucraid has not been tested to see if it works in patients with secondary (acquired) sucrase deficiency. The effects of sacrosidase have not been evaluated in patients with secondary (acquired) disaccharidase deficiencies. Patients with starch intolerance attributable to the isomaltase component may therefore not achieve complete symptom relief with sacrosidase alone and some patients may require continued starch restriction.
Acarbose is a complex oligosaccharide produced in bacteria that has activity against glucoamylase, sucrase, maltase, and isomaltase, intestinal brush border glucosidases. Because acarbose and related drugs (miglitol, voglibose) directly inhibit isomaltase activity, alpha-glucosidase inhibitors inhibit the absorption of carbohydrates from the small intestine, competitively inhibiting enzymes that convert complex nonabsorbable carbohydrates into simple absorbable carbohydrates, including isomaltase. This represents a functional interaction: any endogenous or exogenous isomaltase activity would be competitively suppressed in the presence of these agents. Alpha-glucosidase inhibitors are contraindicated in conditions that can be worsened due to excess gas formation in the gut, and also in patients with partial intestinal obstruction or a predisposition or risk of intestinal obstruction.
Several herbal folk remedies, especially those with polyphenolic components, exert an inhibitory effect on SI. Research on specific polyphenols shows that human sucrase activity was more susceptible than the rat enzyme to inhibition by acarbose, by a polyphenol-rich green tea extract, and by pure (−)-epigallocatechin gallate (EGCG). Four structurally related flavonols (quercetin, kaempferol, quercetagetin, and galangin) have been evaluated individually for their ability to inhibit human α-glucosidases including isomaltase. These interactions are primarily characterized in vitro; human clinical implications are not yet fully established.
N-butyldeoxynojirimycin (miglustat), used for treatment of lysosomal storage diseases, can heavily inhibit SI and thus result in gastrointestinal symptoms in the majority of patients. Codeine as a pain medication and ranitidine with antihistamine effect can also inhibit sucrase activity in the intestine. These findings suggest that patients on these medications may experience secondary reduction of SI activity and consequent carbohydrate malabsorption symptoms.
Enzymatic activity is destroyed by heat. The approved sacrosidase preparation carries an explicit instruction: never heat Sucraid or put it in warm or hot beverages or infant formula. This is a practical consideration for any enzyme-based preparation, as denaturation abolishes catalytic activity.
Further research is needed to clarify the true prevalence of SI deficiency, the pathobiology of single SI heterozygous mutations, and to define optimal diagnostic and treatment algorithms in the pediatric population. Further research is needed to clarify the true prevalence of SI deficiency, the pathobiology of single SI heterozygous mutations, and to define optimal diagnostic and treatment algorithms in the pediatric population.
A fundamental therapeutic gap remains: there is no FDA-approved isomaltase-only therapy. Approved enzyme therapy targets sucrase (sacrosidase) for CSID; dietary management remains central for alpha-1,6 intolerance features. Research into the development of exogenous isomaltase preparations, or therapies targeting the isomaltase component of the SI complex specifically, represents an unmet clinical need. The discovery that homozygous loss-of-function carriers in Greenlandic populations have a healthier metabolic profile (making it possible to study people with loss of SI function in an unbiased way, with a recent study reporting that adult homozygous carriers have a markedly healthier metabolic profile) suggests complex, potentially bidirectional relationships between SI activity and metabolic health that warrant further investigation.
Health conditions that Isomaltase may help support.
Body systems that Isomaltase may help support.
Go back